Melanoma Institute Australia

This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can shrink or eliminate skin cancer in people with stage II to IV cutaneous squamous cell carcinoma. About 20 adults will receive the drugs for 6 weeks, then have surgery to remove a…

This study tests whether removing only the largest affected lymph node (instead of all nearby lymph nodes) after 6 weeks of standard immunotherapy works just as well for stage III melanoma. About 1500 adults with stage IIIB-D melanoma will be randomly assigned to one of the two s…

This phase 2 trial is testing whether adding a precise type of radiation called SBRT to standard immunotherapy helps people with advanced melanoma that has spread to a few spots live longer. About 129 adults with untreated, stage IV melanoma will either get immunotherapy alone or…

This study tests whether giving new combinations of immunotherapy drugs before surgery can improve outcomes for people with advanced melanoma that is hard to treat. About 494 participants with stage 3 skin or mucosal melanoma will receive different drug combinations before their …

This study tests whether giving two immunotherapy drugs (nivolumab and relatlimab) before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 20 adults with stage I to III resectable cancer will receive the drugs for six weeks, then have …

This study is for people with stage IV melanoma that has spread to the brain. It compares two treatments: a combination of two immunotherapy drugs (ipilimumab and nivolumab) alone, or the same drugs plus precise, targeted radiation to the brain tumors. The goal is to see if addin…

This study is testing a new predictive model that analyzes tumor samples to forecast whether a patient with melanoma or other skin cancers will respond to immunotherapy. Researchers will compare the model's predictions with actual patient outcomes over six months. The goal is to …